COMMUNIQUÉS West-GlobeNewswire

Firefly Neuroscience to Participate in Upcoming October Investor Conferences

11/10/2024 - 15:00

TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain [...]

NEXGEL to Participate in Upcoming October Investor Conferences

11/10/2024 - 15:00

LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]

PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing

11/10/2024 - 15:05

Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology, accelerating breakthroughs in cancer genomics across Asia SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a [...]

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

11/10/2024 - 15:15

-Data Supports Deramiocel’s Sustained Efficacy and Safety in Treating DMD- -Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating Stabilization of Cardiac and Skeletal Muscle Function Over 3 Years [...]

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

11/10/2024 - 15:20

Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule [...]

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

11/10/2024 - 15:31

HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of [...]

ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA

11/10/2024 - 15:43

ANNOUNCEMENT NO. 278 11 October 2024 ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA As mentioned in company announcement no. 276, ChemoMetec has made an indicative purchase offer for the Belgian company [...]

The Hemp Doctor Unveils New 1G Liquid Diamond Disposable 75% THCA Vape

11/10/2024 - 16:52

MOORESVILLE, N.C., Oct. 11, 2024 (GLOBE NEWSWIRE) -- The Hemp Doctor, a leader in high-quality hemp products, is excited to announce the launch of its newest innovation: the 1G Liquid Diamond Disposable THCA Vape . [...]

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

11/10/2024 - 18:12

Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy. Expanding its pipeline to include non-oncology products, an opportunistic approach aimed at [...]

HeartFlow Announces Favorable Coverage Determination for Plaque Analysis by Four Medicare Administrative Contractors

11/10/2024 - 18:27

Coverage policy improves access to artificial intelligence-enabled plaque analysis providing insights to help physicians guide treatment decisions for patients with coronary artery disease MOUNTAIN VIEW, Calif., Oct. 11 [...]

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

11/10/2024 - 18:30

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from [...]

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

11/10/2024 - 21:59

WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T [...]

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

11/10/2024 - 22:00

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom’s macroglobulinemia, [...]

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11/10/2024 - 22:05

SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

11/10/2024 - 22:15

Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 11 oct. 2024 (GLOBE NEWSWIRE) -- Paris, France, le 11 octobre 2024 Place de cotation : [...]

Voting Rights and Shares Capital of the Company

11/10/2024 - 22:15

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 11, 2024 (GLOBE NEWSWIRE [...]

Conavi Medical Corp. (formerly “Titan Medical Inc.”) Completes Business Combination

11/10/2024 - 22:30

TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (formerly, “ Titan Medical Inc. ”) (“the “ Resulting Issuer ” or the “ Corporation ”) (TSX: TMD; OTC: TMDIF) is pleased to announce the completion of the [...]

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11/10/2024 - 22:30

CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]

Bionano Announces Preliminary 3Q 2024 Revenues and Cash

10/10/2024 - 14:00

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced select preliminary results for the quarter ended September 30, 2024. The Company now expects revenue for the third [...]